Iron Supplementation for Perioperative Anaemia in Patient Blood Management - European Medical Journal

Iron Supplementation for Perioperative Anaemia in Patient Blood Management

Download PDF
*Manuel Muñoz,1 Susana Gómez-Ramírez,2 Arturo Campos3

Manuel Muñoz has received honoraria for consultancy or lectures and/or travel support from Stryker Ibérica (Spain), Wellspect HealthCare (Sweden), Ferrer Pharma (Spain), Roche (Spain), Vifor Pharma (Spain & Switzerland), PharmaCosmos (Denmark), and Zambon (Spain) but not for this work. Susana Gómez-Ramírez and Arturo Campos have nothing to declare.

EMJ Hema. ;1[1]:123-132. DOI/10.33590/emjhematol/10312664.
Anaemia, surgery, transfusion, intravenous iron, erythropoiesis stimulating agents, patient blood management.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


In patients undergoing major surgical procedures, preoperative anaemia and perioperative allogeneic blood transfusion (ABT) have been linked to increased postoperative morbidity and mortality, as well as longer hospital stays. A multidisciplinary, multimodal, individualised strategy – collectively termed patient blood management – used to minimise or eliminate ABT is indicated to improve outcomes. This new standard of care relies on detection and treatment of perioperative anaemia (Pillar 1) and reduction of surgical blood loss and perioperative coagulopathy (Pillar 2) to harness and optimise physiological tolerance of anaemia (Pillar 3), thus allowing the use of restrictive transfusion criteria. Normalisation of preoperative hemoglobin levels is a World Heath Organization recommendation. Iron repletion should be routinely ordered when indicated. Preoperative oral iron is time-consuming and poorly tolerated with low adherence in published trials. Postoperative oral iron has been proven to be inefficacious and is no longer recommended. Preoperative and perioperative intravenous iron, with or without erythropoiesis stimulating agents, is safe and effective at reducing ABT rate and hastening the recovery from postoperative anaemia. Intravenous iron does not seem to increase the risk for postoperative thromboembolism, infection, or mortality. Newer intravenous iron formulations demonstrate potentially much lower immunogenic activity, allow complete replacement dosing in 15 to 60 minutes, markedly facilitating care, and may be cost-effective in many clinical settings.

Please view the full content in the pdf above.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally